<?xml version="1.0" encoding="UTF-8"?><meta xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns="http://www.w3.org/1999/xhtml" xmlns:xi="http://www.w3.org/2001/XInclude" http-equiv="Content-Type" content="text/html; charset=utf-8" />
<style xmlns:fo="http://www.w3.org/1999/XSL/Format" xmlns:xi="http://www.w3.org/2001/XInclude" type="text/css">
   @media screen{
   .test-story-main legend{
   text-align:center;
   font-size:110%;
   font-weight:bold;
   }
   .test-story-main .nav-tabs{
   font-weight:bold;
   }
   .test-story-main .tds_obxGrpSpl{
   background:#B8B8B8;
   }
   .test-story-main maskByMediaType{
   display:table;
   }
   .test-story-main table tbody tr th{
   font-size:95%
   }
   .test-story-main table tbody tr td{
   font-size: 110%;
   }
   .test-story-main table tbody tr th{
   text-align:left;
   background:#C6DEFF;
   font-size:100%;
   }
   .test-story-main fieldset{
   text-align:center;
   }
   .test-story-main table{
   width:98%;
   border:1px groove;
   table-layout:fixed;
   margin:0 auto;
   border-collapse:collapse;
   }
   .test-story-main table tr{
   border:2px groove;
   
   }
   .test-story-main table th{
   border:2px groove;
   
   }
   .test-story-main table td{
   border:1px groove;
   
   }
   .test-story-main table thead{
   border:1px groove;
   background:#446BEC;
   text-align:center;
   }
   .test-story-main .separator{
   background:rgb(240, 240, 255);
   text-align:left;
   }
   .test-story-main table tbody tr td{
   text-align:left
   }
   .test-story-main .noData{
   background:#B8B8B8;
   }
   .test-story-main .childField{
   background:#B8B8B8;
   }
   .test-story-main .title{
   text-align:left;
   }
   .test-story-main h3{
   text-align:center;
   page-break-inside:avoid;
   }
   .test-story-main h2{
   text-align:center;
   }
   .test-story-main h1{
   text-align:center;
   }
   .test-story-main .pgBrk{
   padding-top:15px;
   }
   .test-story-main .er7Msg{
   width:100%;
   }
   .test-story-main .embSpace{
   padding-left:15px;
   }
   .test-story-main .accordion-heading{
   font-weight:bold;
   font-size:90%;
   }
   .test-story-main .accordion-heading i.fa:after{
   content:"\00a0 ";
   }
   .test-story-main panel{
   margin:10px 5px 5px 5px;
   }
   }
   
   @media print{
   .test-story-main legend{
   text-align:center;
   font-size:110%;
   font-weight:bold;
   }
   .test-story-main .nav-tabs{
   font-weight:bold;
   }
   .test-story-main .obxGrpSpl{
   background:#B8B8B8;
   }
   .test-story-main maskByMediaType{
   display:table;
   }
   .test-story-main table tbody tr th{
   font-size:90%
   }
   .test-story-main table tbody tr td{
   font-size:90%;
   }
   .test-story-main table tbody tr th{
   text-align:left;
   background:#C6DEFF;
   
   }
   .test-story-main table thead tr th{
   text-align:center;
   background:#4682B4;
   
   }
   .test-story-main fieldset{
   text-align:center;
   page-break-inside:avoid;
   }
   .test-story-main table{
   width:98%;
   border:1px groove;
   table-layout:fixed;
   margin:0 auto;
   page-break-inside:avoid;
   border-collapse:collapse;
   }
   .test-story-main table tr{
   border:2px groove;
   }
   .test-story-main table th{
   border:2px groove;
   }
   .test-story-main table td{
   border:1px groove;
   }
   .test-story-main table thead{
   border:1px groove;
   background:#446BEC;
   text-align:left;
   }
   .test-story-main .separator{
   background:rgb(240, 240, 255);
   text-align:left;
   }
   .test-story-main table tbody tr td{
   text-align:left;
   }
   .test-story-main .noData{
   background:#B8B8B8;
   }
   .test-story-main .childField{
   background:#B8B8B8;
   }
   .test-story-main .tds_title{
   text-align:left;
   margin-bottom:1%
   }
   .test-story-main h3{
   text-align:center;
   }
   .test-story-main h2{
   text-align:center;
   }
   .test-story-main h1{
   text-align:center;
   }
   .test-story-main .tds_pgBrk{
   page-break-after:always;
   }
   .test-story-main #er7Message table{
   border:0px;
   width:80%
   }
   .test-story-main #er7Message td{
   background:#B8B8B8;
   font-size:65%;
   margin-top:6.0pt;
   border:0px;
   text-wrap:preserve-breaks;
   white-space:pre;
   }
   .test-story-main .er7Msg{
   width:100%;
   font-size:80%;
   }
   .test-story-main .er7MsgNote{
   width:100%;
   font-style:italic;
   font-size:80%;
   }
   .test-story-main .embSpace{
   padding-left:15px;
   }
   .test-story-main .embSubSpace{
   padding-left:25px;
   }
   .test-story-main .accordion-heading{
   font-weight:bold;
   font-size:90%;
   }
   .test-story-main .accordion-heading i.fa:after{
   content:"\00a0 ";
   }
   .test-story-main panel{
   margin:10px 5px 5px 5px;
   }
   }
</style>
<!-- generated by TestStory_v1.xslt Version:1.0   Profile:TestStory-->
<fieldset>
	<div class="test-story-main">
		<tabset>
			<tab heading="FULL"  vertical="false">
				<div class="panel-body">
					<div class="panel-body"><table><tr><th>Description</th></tr><tr><td><p>CDC identified a new variant of tick-borne Heartland disease causing rapid and significant development of leucopenia, thrombocytopenia, high propensity for intracerebral hemorrhage, and renal failure. The incidence rose sharply beginning March 2024 due to climate change with proliferation of lone star ticks (Amblyomma americanum) and their rapid spread to northern and western states. Due to the increase in disease incidence and severity, the White House established a Heartland Disease Commission and funded rapid development of Heartland-24 vaccine. The first such vaccine, Heartland-24_mRNA just became available but it has not yet been added to commercial drug knowledge bases. The vaccine is available to physician practices and pharmacies but the coding must be added to existing content available in commerical drug knowledge bases. Heartland-24_mRNA vaccine is a single-dose vaccine, given IM, and recommended for all adults over the age of 50 residing in or frequenting non-urban environments.</p><p><br></p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Pre-condition</th></tr><tr><td><p>Availability of new vaccine data CVX, NDC (provided in evaluation criteria)<br><br></p><p><br></p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Post-Condition</th></tr><tr><td><p>The new vaccine codes exists in the SUT.</p><p>Go to step 7.1.2</p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Test Objectives</th></tr><tr><td><p>To test the ability that the SUT can support the entry of newly developed vaccine code sets.<br><br></p><p><br></p></td></tr></table></div><br/><div class="panel-body"><table><tr><th>Evaluation Criteria</th></tr><tr><td><p>New vaccine codes are available in the SUT with minimum data elements as noted below:</p><p>If not all displayed then SUT must explain how the data are made available.</p><table border="0" cellpadding="0" cellspacing="0" width="556"><tbody><tr height="42"><td height="42" width="321">Product Name (This may vary with each implementation)</td><td width="235">Heartland-24_mRNA</td></tr><tr height="21"><td height="21" width="321">Unit-of-Sale (Box) NDC</td><td>8077-0743-15</td></tr><tr height="21"><td height="21" width="321">Unit-of-Use (Syringe or Vial) NDC</td><td>8077-0743-15</td></tr><tr height="21"><td height="21" width="321">Generic Name (CVX 234)</td><td>HVV</td></tr><tr height="21"><td height="21" width="321">Manufacturer</td><td>Moderna</td></tr><tr height="20"><td height="20">Lot Number</td><td>HVV8071524</td></tr><tr height="21"><td height="21" width="321">Expiration Date</td><td>09/27/2029</td></tr><tr height="21"><td height="21" width="321">Funding Source</td><td>Public</td></tr><tr height="20"><td height="20">CVX Code</td><td>234</td></tr><tr height="21"><td height="21" width="321">MVX Code</td><td>MOD</td></tr><tr height="21"><td height="21" width="321">Expiration Date</td><td>20290731</td></tr><tr height="21"><td height="21" width="321">Packaging</td><td>Unknown</td></tr><tr height="21"><td height="21" width="321">Trade Name</td><td>Heartland Virus Vax</td></tr><tr height="20"><td height="20" width="321">Vaccine Information Sheet:&nbsp;</td><td width="235">Heartland-24 Vaccine 03-28-2024 VIS</td></tr><tr height="20"><td height="20" width="321">Program Code &amp; description</td><td width="235">IIP024/HeartlandVV-Program</td></tr></tbody></table><table border="0" cellpadding="0" cellspacing="0" width="556"><tbody><tr height="20"><td height="20" width="321">VIS Fully-encoded text string</td><td width="235">253088698300023411240207</td></tr></tbody></table></td></tr></table></div><br/>
				</div>
			</tab>
			<tab heading="Description" vertical="false"><div class="panel-body"><table><tr><th>Description</th></tr><tr><td><p>CDC identified a new variant of tick-borne Heartland disease causing rapid and significant development of leucopenia, thrombocytopenia, high propensity for intracerebral hemorrhage, and renal failure. The incidence rose sharply beginning March 2024 due to climate change with proliferation of lone star ticks (Amblyomma americanum) and their rapid spread to northern and western states. Due to the increase in disease incidence and severity, the White House established a Heartland Disease Commission and funded rapid development of Heartland-24 vaccine. The first such vaccine, Heartland-24_mRNA just became available but it has not yet been added to commercial drug knowledge bases. The vaccine is available to physician practices and pharmacies but the coding must be added to existing content available in commerical drug knowledge bases. Heartland-24_mRNA vaccine is a single-dose vaccine, given IM, and recommended for all adults over the age of 50 residing in or frequenting non-urban environments.</p><p><br></p></td></tr></table></div></tab><tab heading="Pre-condition" vertical="false"><div class="panel-body"><table><tr><th>Pre-condition</th></tr><tr><td><p>Availability of new vaccine data CVX, NDC (provided in evaluation criteria)<br><br></p><p><br></p></td></tr></table></div></tab><tab heading="Post-Condition" vertical="false"><div class="panel-body"><table><tr><th>Post-Condition</th></tr><tr><td><p>The new vaccine codes exists in the SUT.</p><p>Go to step 7.1.2</p></td></tr></table></div></tab><tab heading="Test Objectives" vertical="false"><div class="panel-body"><table><tr><th>Test Objectives</th></tr><tr><td><p>To test the ability that the SUT can support the entry of newly developed vaccine code sets.<br><br></p><p><br></p></td></tr></table></div></tab><tab heading="Evaluation Criteria" vertical="false"><div class="panel-body"><table><tr><th>Evaluation Criteria</th></tr><tr><td><p>New vaccine codes are available in the SUT with minimum data elements as noted below:</p><p>If not all displayed then SUT must explain how the data are made available.</p><table border="0" cellpadding="0" cellspacing="0" width="556"><tbody><tr height="42"><td height="42" width="321">Product Name (This may vary with each implementation)</td><td width="235">Heartland-24_mRNA</td></tr><tr height="21"><td height="21" width="321">Unit-of-Sale (Box) NDC</td><td>8077-0743-15</td></tr><tr height="21"><td height="21" width="321">Unit-of-Use (Syringe or Vial) NDC</td><td>8077-0743-15</td></tr><tr height="21"><td height="21" width="321">Generic Name (CVX 234)</td><td>HVV</td></tr><tr height="21"><td height="21" width="321">Manufacturer</td><td>Moderna</td></tr><tr height="20"><td height="20">Lot Number</td><td>HVV8071524</td></tr><tr height="21"><td height="21" width="321">Expiration Date</td><td>09/27/2029</td></tr><tr height="21"><td height="21" width="321">Funding Source</td><td>Public</td></tr><tr height="20"><td height="20">CVX Code</td><td>234</td></tr><tr height="21"><td height="21" width="321">MVX Code</td><td>MOD</td></tr><tr height="21"><td height="21" width="321">Expiration Date</td><td>20290731</td></tr><tr height="21"><td height="21" width="321">Packaging</td><td>Unknown</td></tr><tr height="21"><td height="21" width="321">Trade Name</td><td>Heartland Virus Vax</td></tr><tr height="20"><td height="20" width="321">Vaccine Information Sheet:&nbsp;</td><td width="235">Heartland-24 Vaccine 03-28-2024 VIS</td></tr><tr height="20"><td height="20" width="321">Program Code &amp; description</td><td width="235">IIP024/HeartlandVV-Program</td></tr></tbody></table><table border="0" cellpadding="0" cellspacing="0" width="556"><tbody><tr height="20"><td height="20" width="321">VIS Fully-encoded text string</td><td width="235">253088698300023411240207</td></tr></tbody></table></td></tr></table></div></tab>
		</tabset>
	</div>
</fieldset>